Kang Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kang Du has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Haohao Wu
Department of Neurology, Affiliated Qujing Hospital of Kunming Medical University/Qujing Central Hospital of Yunnan Province
6 shared publications- Yun Yuan
Department of Neurology, Peking University First Hospital
5 shared publications - Lingchao Meng
Department of Neurology Peking University First Hospital Beijing China
4 shared publications Wei Zhang
Department of Endocrinology and Metabolism, Yunnan Qujing Central Hospital (Qujing First People’s Hospital)
4 shared publications- Zhaoxia Wang
Department of Neurology Peking University First Hospital Beijing China
4 shared publications Baogang Huang
Department of Neurology, Yunnan Qujing Central Hospital (Qujing First People’s Hospital), Yunnan, China
3 shared publications
Latest Publications
- 2 September 2026
- Published by Taylor & Francis in Immunotherapy
- Vol. 18 (13) , 1127-1133
Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
1. Guillain–Barre syndrome (GBS) is an acute inflammatory polyradiculoneuropathy, with an annual global incidence of 1–2 per 100,000, and is one of the leading causes of acute flaccid paralysis [1,...
- 2 September 2026
- Published by Taylor & Francis in Immunotherapy
- Vol. 18 (13) , 1127-1133
Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
1. Guillain–Barre syndrome (GBS) is an acute inflammatory polyradiculoneuropathy, with an annual global incidence of 1–2 per 100,000, and is one of the leading causes of acute flaccid paralysis [1,...
- Open Access
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Big Data
- Vol. 9, 1832790
Machine learning approach for predicting the severity risk of obstructive sleep apnea syndrome
Background: Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) has a high global prevalence and is prone to causing various serious complications. Our objective is to develop severity stratification of OSAHS by integrating multiple commonly available clinical features based on machine learning (ML). Materials and methods: This study collected data from 432 cases at Qujing Central Hospital in Yunnan Province, integrating 25 clinical feature variables. The cases were randomly split into training (70%) and validation (30%) sets. The importance of the 25 features was analyzed. Results: It showed that the HCY, TBIL, BMI, GGT, and Age made significant contributions to OSAHS severity. We established five machine learning models-Multilayer Perceptron (MLP), Random Forest, XGBoost, LightGBM, and Support Vector Machine (SVM)-by integrating 25 clinical features. Through cross-validation and continuous adjustment of model parameters, the optimal predictive model was determined. By calculating model accuracy and F 1-score, XGBoost was identified as the best-performing model, achieving an area under the curve (AUC) of 0.63, an accuracy of 75% and an F 1-score of 65.60. Conclusion: In this study, we established a predictive model for the severity stratification of OSAHS based on machine learning algorithms. The XGBoost model demonstrated superior predictive performance.
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Big Data
- Vol. 9, 1832790
Open AccessMachine learning approach for predicting the severity risk of obstructive sleep apnea syndrome
Background: Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) has a high global prevalence and is prone to causing various serious complications. Our objective is to develop severity stratification of OSAHS by integrating multiple commonly available clinical features based on machine learning (ML). Materials and methods: This study collected data from 432 cases at Qujing Central Hospital in Yunnan Province, integrating 25 clinical feature variables. The cases were randomly split into training (70%) and validation (30%) sets. The importance of the 25 features was analyzed. Results: It showed that the HCY, TBIL, BMI, GGT, and Age made significant contributions to OSAHS severity. We established five machine learning models-Multilayer Perceptron (MLP), Random Forest, XGBoost, LightGBM, and Support Vector Machine (SVM)-by integrating 25 clinical features. Through cross-validation and continuous adjustment of model parameters, the optimal predictive model was determined. By calculating model accuracy and F 1-score, XGBoost was identified as the best-performing model, achieving an area under the curve (AUC) of 0.63, an accuracy of 75% and an F 1-score of 65.60. Conclusion: In this study, we established a predictive model for the severity stratification of OSAHS based on machine learning algorithms. The XGBoost model demonstrated superior predictive performance.
- Open Access
- 5 February 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1668022
POLR3A-related syndrome complicated with cerebral abscesses: a case report and literature review
Background: POLR3A gene-related syndrome is a complex genetic disorder with diverse clinical manifestations. Understanding its characteristics is crucial for diagnosis and management. Previous studies have reported various aspects of this syndrome, yet a comprehensive analysis of different Variant sites and their associated phenotypes remains necessary. Case report: This study presents a case of POLR3A -related syndrome in a pediatric patient. Symptom onset occurred after 2 years of age, initially presenting with gait disturbance. As the disease progressed, gait instability worsened progressively and was accompanied by dysarthria, intellectual developmental impairment, and tremor. Subsequent neuroimaging revealed multiple intracerebral infectious lesions with abscess formation. Whole-genome sequencing identified a homozygous c.1771-6C>G variant in the POLR3A gene. This variant has been previously reported as pathogenic at this locus; however, the complication of multiple intracerebral infections and abscess formation represents a previously unreported manifestation. It is noteworthy that the parents of the proband were consanguineous (first-degree relatives). Conclusion: A review of 60 unrelated probands with POLR3A -related syndrome was conducted based on previously published cases. The analysis revealed no significant sex difference in disease occurrence. The median age of onset was approximately 8 years, with common initial symptoms including gait disturbance and cognitive developmental impairment. Neuroimaging findings indicated cerebral atrophy in 31 cases (66.0%) and white matter hypomyelination in 17 cases (34.7%). Among the reported genetic variants, c.1909 + 22G>A was the most prevalent, identified in 19 families (17.8%), followed by c.1771-6C>G in 9 families (6.4%). Furthermore, patients with different variant sites displayed heterogeneity in initial symptoms, clinical presentations, and imaging characteristics. This comprehensive review enhances the understanding of the phenotypic and genotypic spectrum of POLR3A -related syndrome.
- 5 February 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1668022
Open AccessPOLR3A-related syndrome complicated with cerebral abscesses: a case report and literature review
Background: POLR3A gene-related syndrome is a complex genetic disorder with diverse clinical manifestations. Understanding its characteristics is crucial for diagnosis and management. Previous studies have reported various aspects of this syndrome, yet a comprehensive analysis of different Variant sites and their associated phenotypes remains necessary. Case report: This study presents a case of POLR3A -related syndrome in a pediatric patient. Symptom onset occurred after 2 years of age, initially presenting with gait disturbance. As the disease progressed, gait instability worsened progressively and was accompanied by dysarthria, intellectual developmental impairment, and tremor. Subsequent neuroimaging revealed multiple intracerebral infectious lesions with abscess formation. Whole-genome sequencing identified a homozygous c.1771-6C>G variant in the POLR3A gene. This variant has been previously reported as pathogenic at this locus; however, the complication of multiple intracerebral infections and abscess formation represents a previously unreported manifestation. It is noteworthy that the parents of the proband were consanguineous (first-degree relatives). Conclusion: A review of 60 unrelated probands with POLR3A -related syndrome was conducted based on previously published cases. The analysis revealed no significant sex difference in disease occurrence. The median age of onset was approximately 8 years, with common initial symptoms including gait disturbance and cognitive developmental impairment. Neuroimaging findings indicated cerebral atrophy in 31 cases (66.0%) and white matter hypomyelination in 17 cases (34.7%). Among the reported genetic variants, c.1909 + 22G>A was the most prevalent, identified in 19 families (17.8%), followed by c.1771-6C>G in 9 families (6.4%). Furthermore, patients with different variant sites displayed heterogeneity in initial symptoms, clinical presentations, and imaging characteristics. This comprehensive review enhances the understanding of the phenotypic and genotypic spectrum of POLR3A -related syndrome.
- Open Access
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1679404
Clinical characteristics of myasthenia gravis patients with coexistence of AChR and titin antibodies
Objective: This study aimed to investigate the clinical characteristics of patients with myasthenia gravis (MG) who are double-seropositive for acetylcholine receptor antibodies (AChR-Ab + ) and titin antibodies (Titin-Ab + ). Methods: A retrospective analysis was conducted on MG patients hospitalized in the Department of Neurology between March 2020 and June 2024. Patients were categorized into two groups based on antibody profiles: those with AChR antibody positivity alone and those with dual positivity for AChR and titin antibodies. Clinical features, MG classification, and treatment outcomes were compared between the two groups. Results: A total of 35 MG patients were included, comprising 18 with single AChR-Ab + and 17 with AChR-Ab + /Titin-Ab + . The dual antibody-positive group showed a significantly higher proportion of patients with MGFA classification above Class II (47.1%) and a higher rate of thyroid dysfunction (50%) compared to the single antibody-positive group ( p = 0.001). The median age of onset in the dual antibody-positive group was older than that in the single antibody-positive group (67.0 years vs. 58.5 years), although this difference was not statistically significant ( p > 0.05). No significant differences were observed between the two groups in terms of gender, initial symptoms, clinical manifestations, thymic hyperplasia, proportion of thymoma, treatment regimens, or therapeutic outcomes (all p > 0.05). Conclusion: This study provides the first systematic characterization of the clinical profile of AChR-Ab + /Titin-Ab + myasthenia gravis patients in Southwest China. Our findings indicate that dual antibody-positive MG patients are more prone to generalized disease involvement and have a higher susceptibility to thyroid dysfunction.
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1679404
Open AccessClinical characteristics of myasthenia gravis patients with coexistence of AChR and titin antibodies
Objective: This study aimed to investigate the clinical characteristics of patients with myasthenia gravis (MG) who are double-seropositive for acetylcholine receptor antibodies (AChR-Ab + ) and titin antibodies (Titin-Ab + ). Methods: A retrospective analysis was conducted on MG patients hospitalized in the Department of Neurology between March 2020 and June 2024. Patients were categorized into two groups based on antibody profiles: those with AChR antibody positivity alone and those with dual positivity for AChR and titin antibodies. Clinical features, MG classification, and treatment outcomes were compared between the two groups. Results: A total of 35 MG patients were included, comprising 18 with single AChR-Ab + and 17 with AChR-Ab + /Titin-Ab + . The dual antibody-positive group showed a significantly higher proportion of patients with MGFA classification above Class II (47.1%) and a higher rate of thyroid dysfunction (50%) compared to the single antibody-positive group ( p = 0.001). The median age of onset in the dual antibody-positive group was older than that in the single antibody-positive group (67.0 years vs. 58.5 years), although this difference was not statistically significant ( p > 0.05). No significant differences were observed between the two groups in terms of gender, initial symptoms, clinical manifestations, thymic hyperplasia, proportion of thymoma, treatment regimens, or therapeutic outcomes (all p > 0.05). Conclusion: This study provides the first systematic characterization of the clinical profile of AChR-Ab + /Titin-Ab + myasthenia gravis patients in Southwest China. Our findings indicate that dual antibody-positive MG patients are more prone to generalized disease involvement and have a higher susceptibility to thyroid dysfunction.
- 24 November 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 174, 110811
Advances in multimodal artificial intelligence models for epilepsy research
- 24 November 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 174, 110811
Advances in multimodal artificial intelligence models for epilepsy research
- 29 September 2025
- Published by Springer Nature in Neurological Sciences
- p. 1-9
The first report of ceroid lipofuscinosis type 11 in China: a novel mutation of GRN and updated clinical review
Ceroid lipofuscinosis type 11 (CLN11) is an extremely rare inherited neurodegenerative disorder, with only 29 cases reported worldwide to date. Additional case reports are urgently needed to further elucidate the clinical and epidemiological characteristics of this disease. In this study, we report the first documented case of CLN11 in China, which also represents the first globally reported case associated with a novel mutation involving complete deletion of exon 1 in the GRN gene. Moreover, we provide a comprehensive review of the clinical and subclinical features, management strategies, and outcomes of all reported CLN11 cases. For the first time, we propose a simplified clinical scoring system for CLN11 to assess disease severity. Our study may advance current understanding of GRN-related neurodegenerative disorders and expand the phenotypic and genotypic landscape of CLN11.
- 29 September 2025
- Published by Springer Nature in Neurological Sciences
- p. 1-9
The first report of ceroid lipofuscinosis type 11 in China: a novel mutation of GRN and updated clinical review
Ceroid lipofuscinosis type 11 (CLN11) is an extremely rare inherited neurodegenerative disorder, with only 29 cases reported worldwide to date. Additional case reports are urgently needed to further elucidate the clinical and epidemiological characteristics of this disease. In this study, we report the first documented case of CLN11 in China, which also represents the first globally reported case associated with a novel mutation involving complete deletion of exon 1 in the GRN gene. Moreover, we provide a comprehensive review of the clinical and subclinical features, management strategies, and outcomes of all reported CLN11 cases. For the first time, we propose a simplified clinical scoring system for CLN11 to assess disease severity. Our study may advance current understanding of GRN-related neurodegenerative disorders and expand the phenotypic and genotypic landscape of CLN11.
- Open Access
- 13 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (24) , e42796
Interrelationship between PQ exposure and Parkinson disease: A systematic review and meta-analysis
Background: Some studies have conflicting findings, suggesting that PQ has no association with the progression of Parkinson disease (PD). This meta-analysis aimed to investigate the impact of PQ on the incidence of PD. Methods: A computerized search was conducted in Pubmed, Embase, Cochrane, Web of Science, and Scopus for literature on factors influencing DEACMP from their inception to October 2023. Statistical analyses and meta-analyses were performed using STATA 17.0 and RevMan 5.4 software, respectively. Results: A total of 181 articles were retrieved. 14 articles were included, comprising 4731 PD cases and 205,129 control cases. In case-control studies, the proportion of PQ exposure in the PD group was relatively high, with an odds ratio (OR) of 1.47 (95% confidence interval [CI]: 1.25, 1.72; I 2 = 2%, P < .00001). In cohort studies, the PD group showed a relatively high proportion of PQ exposure, with an OR of 0.81 (95% CI: 0.71–0.92; I 2 = 0%, P = .001). Additionally, subgroup analyses were conducted based on the study area. Studies from the United States and Canada indicated that the proportion of PQ exposure in the PD group was relatively high, with an OR of 1.36 (95% CI: 1.12–1.67; I 2 = 10%, P = .002). In addition, the occupational exposure analysis showed that the proportion of PQ exposure in the PD group was higher, with an OR of 0.83 (95% CI: 0.71–0.99; I 2 = 10%, P = .03). The environmental exposure analysis indicated a tendency towards a higher proportion of PQ exposure in the PD group, with an OR of 2.37 (95% CI: 0.98–5.73; I 2 = 9%, P = .06). The mixed exposure analysis revealed a significantly higher proportion of PQ exposure in the PD group, with an OR of 1.47 (95% CI: 1.25–1.73; I 2 = 0%, P < .0001). Conclusions: This study demonstrates that PQ exposure does not obviously increase the incidence of PD. However, factors such as gender, exposure conditions, and regional differences may affect the incidence of PD induced by PQ exposure. Further clarification is required regarding the impact of paraquat exposure on PD. Simultaneously, efforts should be made to prohibit or reduce the use of and exposure to paraquat.
- 13 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (24) , e42796
Open AccessInterrelationship between PQ exposure and Parkinson disease: A systematic review and meta-analysis
Background: Some studies have conflicting findings, suggesting that PQ has no association with the progression of Parkinson disease (PD). This meta-analysis aimed to investigate the impact of PQ on the incidence of PD. Methods: A computerized search was conducted in Pubmed, Embase, Cochrane, Web of Science, and Scopus for literature on factors influencing DEACMP from their inception to October 2023. Statistical analyses and meta-analyses were performed using STATA 17.0 and RevMan 5.4 software, respectively. Results: A total of 181 articles were retrieved. 14 articles were included, comprising 4731 PD cases and 205,129 control cases. In case-control studies, the proportion of PQ exposure in the PD group was relatively high, with an odds ratio (OR) of 1.47 (95% confidence interval [CI]: 1.25, 1.72; I 2 = 2%, P < .00001). In cohort studies, the PD group showed a relatively high proportion of PQ exposure, with an OR of 0.81 (95% CI: 0.71–0.92; I 2 = 0%, P = .001). Additionally, subgroup analyses were conducted based on the study area. Studies from the United States and Canada indicated that the proportion of PQ exposure in the PD group was relatively high, with an OR of 1.36 (95% CI: 1.12–1.67; I 2 = 10%, P = .002). In addition, the occupational exposure analysis showed that the proportion of PQ exposure in the PD group was higher, with an OR of 0.83 (95% CI: 0.71–0.99; I 2 = 10%, P = .03). The environmental exposure analysis indicated a tendency towards a higher proportion of PQ exposure in the PD group, with an OR of 2.37 (95% CI: 0.98–5.73; I 2 = 9%, P = .06). The mixed exposure analysis revealed a significantly higher proportion of PQ exposure in the PD group, with an OR of 1.47 (95% CI: 1.25–1.73; I 2 = 0%, P < .0001). Conclusions: This study demonstrates that PQ exposure does not obviously increase the incidence of PD. However, factors such as gender, exposure conditions, and regional differences may affect the incidence of PD induced by PQ exposure. Further clarification is required regarding the impact of paraquat exposure on PD. Simultaneously, efforts should be made to prohibit or reduce the use of and exposure to paraquat.
- 20 February 2025
- Published by Wiley in Annals of Neurology
- Vol. 97 (6) , 1158-1167
A Multicenter Study of Hereditary Transthyretin Amyloidosis in China
Objective: Hereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant genetic disease characterized by the misfolding and deposition of the transthyretin (TTR) protein. This study aimed to describe the clinical and genetic characteristics of ATTRv in a large multicenter Chinese cohort.Methods: Patients from 14 centers were included in the study. The clinical and genetic characteristics of all patients were summarized. The peripheral blood white blood cell mitochondrial DNA (mtDNA) was detected in offspring from different genders.Results: A total of 202 individuals with ATTRv from 148 families were identified. The average age of onset was 50.6 ± 12.4 years. Among these cases, 117 (57.9%) were classified as late‐onset (≥50 years) and 85 (42.1%) as early‐onset. Overall, the length dependent axonal sensorimotor peripheral neuropathy was the predominant phenotype (89.1%). A total of 42 heterozygous missense variants and 1 deletion variant were identified. The most common variants were Val30Met (19.8%) and Ala97Ser (15.8%) and patients with Val30Met and Ala97Ser were mostly late‐onset in our cohort. Thirty‐nine of these patients died with a mean age of 56.1 ± 13.5 years. Anticipation according to gender groups of offspring‐parent pairs was different, and mother‐son pairs showed the largest anticipation. The copies of mtDNA in the mother's offspring outnumbered those of the father's offspring (p < 0.001).Interpretation: This study highlights that ATTRv patients in China exhibit high heterogeneity in their initial symptoms. The most common variants observed in this cohort is Val30Met. The mtDNA copy number shows gender‐linked effects. These results can impact ATTRv diagnosis and patient care strategies. ANN NEUROL 2025;97:1158–1167
- 20 February 2025
- Published by Wiley in Annals of Neurology
- Vol. 97 (6) , 1158-1167
A Multicenter Study of Hereditary Transthyretin Amyloidosis in China
Objective: Hereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant genetic disease characterized by the misfolding and deposition of the transthyretin (TTR) protein. This study aimed to describe the clinical and genetic characteristics of ATTRv in a large multicenter Chinese cohort.Methods: Patients from 14 centers were included in the study. The clinical and genetic characteristics of all patients were summarized. The peripheral blood white blood cell mitochondrial DNA (mtDNA) was detected in offspring from different genders.Results: A total of 202 individuals with ATTRv from 148 families were identified. The average age of onset was 50.6 ± 12.4 years. Among these cases, 117 (57.9%) were classified as late‐onset (≥50 years) and 85 (42.1%) as early‐onset. Overall, the length dependent axonal sensorimotor peripheral neuropathy was the predominant phenotype (89.1%). A total of 42 heterozygous missense variants and 1 deletion variant were identified. The most common variants were Val30Met (19.8%) and Ala97Ser (15.8%) and patients with Val30Met and Ala97Ser were mostly late‐onset in our cohort. Thirty‐nine of these patients died with a mean age of 56.1 ± 13.5 years. Anticipation according to gender groups of offspring‐parent pairs was different, and mother‐son pairs showed the largest anticipation. The copies of mtDNA in the mother's offspring outnumbered those of the father's offspring (p < 0.001).Interpretation: This study highlights that ATTRv patients in China exhibit high heterogeneity in their initial symptoms. The most common variants observed in this cohort is Val30Met. The mtDNA copy number shows gender‐linked effects. These results can impact ATTRv diagnosis and patient care strategies. ANN NEUROL 2025;97:1158–1167
- Open Access
- 4 September 2024
- Published by Springer Nature in BMC Medical Genomics
- Vol. 17 (1) , 1-7
A novel variant of biallelic MME gene associated with autosomal recessive late-onset distal hereditary motor neuropathy in Chinese families
Distal hereditary motor neuropathies (dHMN) are a group of heterogeneous diseases and previous studies have reported that the compound heterozygous recessive MME variants cause dHMN. Our study found a novel homozygous MME variant and a reported compound heterozygous MME variant in two Chinese families, respectively. Next-generation sequencing and nerve conduction studies were performed for two probands. The probands in two families presented with the muscle weakness and wasting of both lower limbs and carried a c.2122 A > T (p.K708*) and c.1342 C > T&c.2071_2072delinsTT (p.R448*&p.A691L) variant, respectively. Prominently axonal impairment of motor nerves and slight involvement of sensory nerves were observed in nerve conduction study. Our study reported a “novel” nonsense mutation and a missense variant of autosomal recessive late-onset dHMN and reviewed reported MME variants associated with dHMN phenotype.
- 4 September 2024
- Published by Springer Nature in BMC Medical Genomics
- Vol. 17 (1) , 1-7
Open AccessA novel variant of biallelic MME gene associated with autosomal recessive late-onset distal hereditary motor neuropathy in Chinese families
Distal hereditary motor neuropathies (dHMN) are a group of heterogeneous diseases and previous studies have reported that the compound heterozygous recessive MME variants cause dHMN. Our study found a novel homozygous MME variant and a reported compound heterozygous MME variant in two Chinese families, respectively. Next-generation sequencing and nerve conduction studies were performed for two probands. The probands in two families presented with the muscle weakness and wasting of both lower limbs and carried a c.2122 A > T (p.K708*) and c.1342 C > T&c.2071_2072delinsTT (p.R448*&p.A691L) variant, respectively. Prominently axonal impairment of motor nerves and slight involvement of sensory nerves were observed in nerve conduction study. Our study reported a “novel” nonsense mutation and a missense variant of autosomal recessive late-onset dHMN and reviewed reported MME variants associated with dHMN phenotype.
- Open Access
- 12 August 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1393158
Fahr’s syndrome as the initial imaging characteristics of MELAS syndrome with a possible seizure activity and cardiac arrest: a case report
This study reported a case of MELAS syndrome presenting as the initial imaging characteristics of Fahr’s syndrome with “near” sudden unexpected death in epilepsy (SUDEP) and lateralized periodic discharges (LPD). The patient, a young boy, experienced loss of consciousness 2 days prior, which was followed by two limb and facial convulsions. He was later found in cardiac arrest during hospitalization, but regained consciousness gradually after receiving cardiopulmonary resuscitation and tracheal intubation. The patient exhibited short stature, intellectual disability, poor sports abilities, and academic performance since childhood, but had no family history. Emergency head computed tomography (CT) revealed high density calcification in bilateral caudate nucleus, lentiform nucleus, thalamus, and dentate nucleus with evidence of an acute process. The patient was transferred to the neurology department where he continued to recover consciousness, though he experienced dysarthria, left limb hemiplegia, and hemiparesthesia. Changes in head magnetic resonance imaging (MRI) findings were noted at admission, 1 month later, and 6 months later. LPD were observed in his video electroencephalogram. The CT urography indicated a narrow left ureteropelvic junction with left hydronephrosis, which was suggestive of ureteropelvic junction obstruction. Ultimately, a diagnosis of near-SUDEP was suspected in this patient, indicating a rare case of MELAS syndrome with near-SUDEP and LPD. The gene tests results revealed the presence of the mitochondrial DNA A3243G mutation, leading to the final diagnosis of MELAS syndrome. This case expands the clinical disease spectrum of the MELAS syndrome.
- 12 August 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1393158
Open AccessFahr’s syndrome as the initial imaging characteristics of MELAS syndrome with a possible seizure activity and cardiac arrest: a case report
This study reported a case of MELAS syndrome presenting as the initial imaging characteristics of Fahr’s syndrome with “near” sudden unexpected death in epilepsy (SUDEP) and lateralized periodic discharges (LPD). The patient, a young boy, experienced loss of consciousness 2 days prior, which was followed by two limb and facial convulsions. He was later found in cardiac arrest during hospitalization, but regained consciousness gradually after receiving cardiopulmonary resuscitation and tracheal intubation. The patient exhibited short stature, intellectual disability, poor sports abilities, and academic performance since childhood, but had no family history. Emergency head computed tomography (CT) revealed high density calcification in bilateral caudate nucleus, lentiform nucleus, thalamus, and dentate nucleus with evidence of an acute process. The patient was transferred to the neurology department where he continued to recover consciousness, though he experienced dysarthria, left limb hemiplegia, and hemiparesthesia. Changes in head magnetic resonance imaging (MRI) findings were noted at admission, 1 month later, and 6 months later. LPD were observed in his video electroencephalogram. The CT urography indicated a narrow left ureteropelvic junction with left hydronephrosis, which was suggestive of ureteropelvic junction obstruction. Ultimately, a diagnosis of near-SUDEP was suspected in this patient, indicating a rare case of MELAS syndrome with near-SUDEP and LPD. The gene tests results revealed the presence of the mitochondrial DNA A3243G mutation, leading to the final diagnosis of MELAS syndrome. This case expands the clinical disease spectrum of the MELAS syndrome.